BioSpace News Archive

Thirteen of those were development programs, the remaining 25 research-stage. In September, the company indicated it was on a cost-cutting program, planning to save 1.5 billion euros this year. Of the programs it is dumping, the most prominent is a mid-phase drug for respiratory syncytial virus (RSV), ALX-0171.

Mechelen, Belgium, and Hamburg, Germany; 7 February 2019, 7.30 CET - Evotec AG, and Galapagos NV announced a global collaboration focused on a novel target for fibrosis and other indications.

Pharmahungary Group won an SME Instrument Phase I grant with an innovative in-house R&D project, Vezics, www.vezics.com.

The compact NIR backscattering sensor EXspect 271 has an innovative optical measurement system and offers economical and reliable turbidity measurement.

Mimicking how the biological world arranges itself could help advance the next generation of nanomaterials.

Health cluster outlined main objectives during annual event, which gathered more than 200 stakeholders: Medicen will focus on European and international development as well as development of the French precision medicine industry

Current tools used to predict prostate cancer progression are generally subjective in nature, leading to differing interpretations among clinicians

InCrowd’s fourth annual survey shows 95% of responding US physicians want efforts to improve costs in 2019, yet 82% predict these are unlikely; many say “prescribing smart” strategies can help

Shares of Solid Biosciences have plunged more than 71 percent after the company revealed early data from a Phase I/II trial that showed low doses of its gene therapy treatment may lack the potential to be as effective a treatment for Duchenne muscular dystrophy as current products on the market.

Despite a decline over the past year of class-action lawsuits, life science companies remain a popular target for securities fraud litigation.